Mills M - Search Results

1

A Systematic Review of Value Criteria for Next-Generation Sequencing/Comprehensive Genomic Profiling to Inform Value Framework Development.

Augustovski F, Colaci C, Mills M, Chavez D, Argento F, Alfie V, Pichon Riviere A, Kanavos P, Alcaraz A. Augustovski F, et al. Among authors: mills m. Value Health. 2024 May;27(5):670-685. doi: 10.1016/j.jval.2024.02.002. Epub 2024 Feb 23. Value Health. 2024. PMID: 38403113 Free article. Review.

2

How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada.

Mills M, Kanavos P. Mills M, et al. Health Policy. 2022 Nov;126(11):1130-1143. doi: 10.1016/j.healthpol.2022.08.005. Epub 2022 Aug 9. Health Policy. 2022. PMID: 36050193 Free article. Review.

3

Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries.

Mills M, Kanavos P. Mills M, et al. Pharmacoecon Open. 2023 Jul;7(4):553-565. doi: 10.1007/s41669-023-00406-1. Epub 2023 Mar 23. Pharmacoecon Open. 2023. PMID: 36952209 Free PMC article.

4

Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe.

Mills M, Kanavos P. Mills M, et al. Health Policy. 2020 Mar;124(3):239-251. doi: 10.1016/j.healthpol.2019.12.002. Epub 2019 Dec 12. Health Policy. 2020. PMID: 31926651 Review.

5

Sin taxes and their effect on consumption, revenue generation and health improvement: a systematic literature review in Latin America.

Miracolo A, Sophiea M, Mills M, Kanavos P. Miracolo A, et al. Among authors: mills m. Health Policy Plan. 2021 Jun 3;36(5):790-810. doi: 10.1093/heapol/czaa168. Health Policy Plan. 2021. PMID: 33885782 Free PMC article.

6

Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.

Michaeli DT, Mills M, Kanavos P. Michaeli DT, et al. Among authors: mills m. Appl Health Econ Health Policy. 2022 Sep;20(5):757-768. doi: 10.1007/s40258-022-00737-w. Epub 2022 Jul 11. Appl Health Econ Health Policy. 2022. PMID: 35821360 Free PMC article.

7

The future of oncology policy.

Gill JL, Mills MJ, Wharton GA, Kanavos PG. Gill JL, et al. J Cancer Policy. 2022 Dec;34:100352. doi: 10.1016/j.jcpo.2022.100352. Epub 2022 Aug 8. J Cancer Policy. 2022. PMID: 35952940 Free article.

8

Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.

Michaeli DT, Mills M, Michaeli T, Miracolo A, Kanavos P. Michaeli DT, et al. Among authors: mills m. Invest New Drugs. 2022 Aug;40(4):798-809. doi: 10.1007/s10637-022-01227-5. Epub 2022 Apr 7. Invest New Drugs. 2022. PMID: 35389145 Free PMC article.

9

HTA Barriers for Conditional Approval Drugs.

Mills M. Mills M. Pharmacoeconomics. 2023 May;41(5):529-545. doi: 10.1007/s40273-023-01248-9. Epub 2023 Feb 23. Pharmacoeconomics. 2023. PMID: 36821044

10

Women in leadership matters: Achieving diversity in radiology residency recruitment.

Cole HA, Grimm LJ, Omofoye TS, Cooke EA, Heitkamp DE, Mills MK, Wang M, Maxfield CM, Chapman T. Cole HA, et al. Among authors: mills mk. Clin Imaging. 2024 Apr 12;111:110144. doi: 10.1016/j.clinimag.2024.110144. Online ahead of print. Clin Imaging. 2024. PMID: 38749319

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,480 results

Search Page